

ISO 12417-1:2024-02 (E)

Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements

Contents		Page
Foreword		v
Introduction		vi
1	Scope	1
2	Normative references	2
3	Terms and definitions	2
4	Intended performance	6
4.1	General	6
4.2	Classification	6
4.3	Intended clinical location	7
5	Design attributes	7
5.1	General	7
5.2	Drug-containing part of the VDDCP	7
5.2.1	General	7
5.2.2	Matrix	8
5.2.3	Active pharmaceutical ingredient	8
6	Materials	9
7	Design evaluation	9
7.1	General	9
7.2	Pre-clinical evaluation	10
7.2.1	Sampling	10
7.2.2	Conditioning of test samples	10
7.2.3	Pre-clinical in vitro test reports and additional information	11
7.2.4	Pre-clinical in vitro evaluation	11
7.2.5	Preclinical in vivo evaluation	17
7.3	Clinical evaluation	22
7.3.1	Purpose	22
7.3.2	Specific aims	22
7.3.3	Clinical investigation plan	22
7.3.4	Data acquisition	23
7.3.5	Final report	25
7.4	Post-market surveillance	26
8	Manufacturing	26
8.1	General	26
8.2	Raw material reporting and analysis of the API	26
8.3	Raw material analysis and reporting for excipients	27
8.4	VDDCP batch release testing	27
9	Sterilization	28
9.1	Products supplied sterile -- Testing to support "Sterile" labelling	28
9.2	Products supplied non-sterile	28
9.3	Sterilization residuals	28

10	Packaging	28
10.1	General	28
10.2	Considerations for VDDCPs	28
10.3	Impact of changes in storage and shipping temperatures on VDDCP	28
11	Information supplied by the manufacturer	29
11.1	General	29
11.2	Labelling	29
11.2.1	VDDCP label(s)	29
11.2.2	Record label	29
11.3	Instructions for use	30
	Annex A (informative) Description of potential clinical and technical events	31
	Annex B (informative) Local information regarding submission issues for VDDCPs	36
	Bibliography	42